[HTML][HTML] Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis
T Zhou, Y Xie, X Hou, W Bai, X Li, Z Liu, Q Man… - Journal of Experimental …, 2023 - Springer
Background Chemoresistance is the main reason for the poor prognosis of pancreatic ductal
adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and …
adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and …
ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4
T Zhou, J Liu, Y Xie, S Yuan, Y Guo, W Bai, K Zhao… - Gut, 2022 - gut.bmj.com
Background and aims The crosstalk between cancer stem cells (CSCs) and their niche is
required for the maintenance of stem cell-like phenotypes of CSCs. Here, we identified E26 …
required for the maintenance of stem cell-like phenotypes of CSCs. Here, we identified E26 …
[HTML][HTML] Identification of ferroptosis-related genes signature predicting the efficiency of invasion and metastasis ability in colon adenocarcinoma
C Shi, Y Xie, X Li, G Li, W Liu, W Pei, J Liu… - Frontiers in cell and …, 2022 - frontiersin.org
Background: Colon adenocarcinoma (COAD) is one of the most prevalent cancers worldwide
and has become a leading cause of cancer death. Although many potential biomarkers of …
and has become a leading cause of cancer death. Although many potential biomarkers of …
[HTML][HTML] Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma
T Zhou, Q Man, X Li, Y Xie, X Hou, H Wang… - Cancer Biology & …, 2023 - ncbi.nlm.nih.gov
Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T
cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated …
cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated …
[HTML][HTML] A cuproptosis-related lncRNA signature-based prognostic model featuring on metastasis and drug selection strategy for patients with lung adenocarcinoma
M Zhang, Z Xiao, Y Xie, Z Li, L Zhang… - Frontiers in …, 2023 - frontiersin.org
Introduction: Lung adenocarcinoma is a common cause of mortality in patients with cancer.
Recent studies have indicated that copper-related cell death may not occur in the same way …
Recent studies have indicated that copper-related cell death may not occur in the same way …
SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation
J Liu, W Bai, T Zhou, Y Xie, B Yang, J Sun, Y Wang… - Gut, 2023 - gut.bmj.com
Objective Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal tumour with limited
treatment options. Here, we identified syndecan binding protein (SDCBP), also known as …
treatment options. Here, we identified syndecan binding protein (SDCBP), also known as …
Analysis on the mechanism of pulse-shortening in an X-band triaxial klystron amplifier due to the asymmetric mode competition
Z Qi, J Zhang, Y Xie, Y Zhang, Z Wang, X Zhou… - Physics of …, 2016 - pubs.aip.org
Asymmetric mode competitions are observed in the design of an X-band triaxial klystron
amplifier with an asymmetric input cavity, and the generation mechanism of the asymmetric …
amplifier with an asymmetric input cavity, and the generation mechanism of the asymmetric …
Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer
C Liu, X Qian, C Yu, X Xia, J Li, Y Li, Y Xie, G Gao… - Cancer Letters, 2024 - Elsevier
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer. Anti-PD-1/PD-L1
treatment for advanced TNBC is still limited to PD-L1-positive patients. Ataxia …
treatment for advanced TNBC is still limited to PD-L1-positive patients. Ataxia …
[HTML][HTML] Combination of RUNX1 inhibitor and gemcitabine mitigates chemo‐resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis …
C She, C Wu, W Guo, Y Xie, S Li, W Liu, C Xu… - Journal of Experimental …, 2023 - Springer
Background Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic
ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its …
ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its …
Triple‐negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding
X Hou, X Li, Y Han, H Xu, Y Xie, T Zhou, T Xue… - Cancer, 2024 - Wiley Online Library
Background Triple‐negative breast cancer (TNBC) is a highly heterogeneous and clinically
aggressive disease. Accumulating evidence indicates that tertiary lymphoid structures (TLSs) …
aggressive disease. Accumulating evidence indicates that tertiary lymphoid structures (TLSs) …
